Healthcare
SCYNEXIS, Inc.(SCYX)
Live Price
Offline$4.05
+6.58% today
1Y Change
-29.97%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $40.00M
- Revenue Growth
- +449.9%
- EPS Growth
- +61.4%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SCYNEXIS, Inc. (SCYX) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $4.05 and down 30.0% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +449.9%, EPS growth of +61.4%, a dividend yield of 0.0%. What stands out right now is revenue +449.9%, EPS +61.4%, free cash flow +78.0% with operating margin -77.9% and ROIC -29.9%. Valuation is more restrained than many high-expectation growth names at price/sales 2.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SCYX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+449.9% vs +7.6% peer median
Operating Margin
Below sector median
-77.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +449.9% and EPS at +61.4%, with operating margin around -77.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +3.0% | -0.7% | โ |
2026 Mar 4, 2026 | +97.3% | +2.3% | +15.1% | +14.6% |
2025 Nov 5, 2025 | +19.1% | -5.5% | -6.3% | +6.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCYX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SCYX Max Drawdown
-56.67%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SCYX and SPY.
Company Overview
SCYNEXIS, Inc.
NASDAQ Global Market
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
- Leadership
- David Gonzalez Angulo
- IPO Date
- May 2, 2014
- Employees
- 28
- Street Address
- 1 Evertrust Plaza
- Mailing
- Jersey City, NJ, 07302-6548
- Region
- Jersey City, NJ, US
- Reporting Currency
- USD
- Investor Line
- 201 884 5485
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 1.5
- Price/Sales
- 2.1
- Price/Book
- 0.9
Growth
- Revenue
- +449.9%
- EPS
- +61.4%
- Free Cash Flow
- +78.0%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -77.9%
- Net Margin
- -41.8%
- ROE
- -19.0%
- ROIC
- -29.9%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 7.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.